GC-Globulin Patent Claims Diabetes Treatment
Summary
USPTO published patent application US20260098068A1 for GC-globulin or variants for treating diabetes, filed September 22, 2023. The application names David Hodson, Katrina Viloria, and Martin Hewison as inventors and covers compositions and methods for diabetes treatment using the vitamin D-binding protein.
What changed
USPTO published patent application US20260098068A1 covering GC-globulin (vitamin D-binding protein) and variants for diabetes treatment. The application includes claims directed to pharmaceutical compositions and methods of treating diabetes using GC-globulin. The CPC classifications indicate therapeutic applications (A61P 3/10, A61P 3/14) and protein compositions (C07K 14/4717, A61K 38/00).
For pharmaceutical companies and biotech firms developing diabetes treatments, this patent application represents potential prior art and could constrain freedom-to-operate in the GC-globulin treatment space. Researchers and developers should monitor the patent prosecution to assess claim scope upon issuance.
What to do next
- Monitor patent prosecution status for potential licensing opportunities
- Review claims for freedom-to-operate analysis in diabetes therapeutics
- Evaluate potential partnership or acquisition of patent rights
Archived snapshot
Apr 9, 2026GovPing captured this document from the original source. If the source has since changed or been removed, this is the text as it existed at that time.
GC-GLOBULIN FOR USE IN TREATING DIABETES
Application US20260098068A1 Kind: A1 Apr 09, 2026
Inventors
DAVID HODSON, Katrina VILORIA, Martin HEWISON
Abstract
The invention relates to GC-globulin, or a variant thereof, for use in treating diabetes.
CPC Classifications
C07K 14/4717 A61P 3/10 A61P 3/14 A61K 38/00
Filing Date
2023-09-22
Application No.
19114441
Related changes
Get daily alerts for USPTO Patent Applications - Peptides (C07K)
Daily digest delivered to your inbox.
Free. Unsubscribe anytime.
Source
About this page
Every important government, regulator, and court update from around the world. One place. Real-time. Free. Our mission
Source document text, dates, docket IDs, and authority are extracted directly from USPTO.
The plain-English summary, classification, and "what to do next" steps are AI-generated from the original text. Cite the source document, not the AI analysis.
Classification
Who this affects
Taxonomy
Browse Categories
Get alerts for this source
We'll email you when USPTO Patent Applications - Peptides (C07K) publishes new changes.